Kodjikian L, Lecleire-Collet A, Dot C, et al. - In this real-world prospective observational 24-month study, researchers sought to assess the real-world effectiveness of intravitreal ranibizumab 0.5 mg (Lucentis) in improving visual acuity (VA) in adults with decreased VA due to diabetic macular edema (DME). Ranibizumab-naïve patients (n = 116) were recruited, treated and followed up according to investigators’ usual procedures. Despite using fewer injections than recommended, real-world ranibizumab treatment improved VA in DME patients.